MCG
PCSA icon

McCollum Christoferson Group’s Processa Pharmaceuticals PCSA Stock Holding History

McCollum Christoferson Group’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25
Closed -$4.18K – 67
2023
Q4 		$4.18K Buy
+25
New +$5.58K ﹤0.01% 65

Other funds holding PCSA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

McCollum Christoferson Group's PCSA Position: Q1 2024 in Review

McCollum Christoferson Group sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 25 shares — an estimated $4.18K sold.

McCollum Christoferson Group first reported a position in PCSA in Q4 2023 and held it in 1 quarter. The position peaked at $4.18K in Q4 2023. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

  • McCollum Christoferson Group reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • McCollum Christoferson Group sold 25 Processa Pharmaceuticals shares in Q1 2024, an estimated $4.18K.
  • McCollum Christoferson Group first reported a position in Processa Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • McCollum Christoferson Group's Processa Pharmaceuticals position peaked at $4.18K in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on McCollum Christoferson Group's 13F filing for Q1 2024, filed 26 Apr 2024.